Topiramate and severe metabolic acidosis: Case report

Arquivos de Neuro-Psiquiatria

Volumn 63, Issue 2 B, 2005, Pages 532-534

  Burmeister, Jayme E ^a,b   Pereira, Rafael R ^a   Hartke, Elisa M ^a   Kreuz, Michele ^a  

^a UNIVERSIDADE LUTERANA DO BRASIL   (Brazil)

^b Department of Clinical Medicine and Nephrology ^*  (Brazil)

Author keywords

Carbonic anhydrase inhibitor; Metabolic acidosis; Topiramate

Indexed keywords

CARBONATE DEHYDRATASE; CARBONATE DEHYDRATASE INHIBITOR; TOPIRAMATE;

ACID BASE BALANCE; ADULT; ANION GAP; ARTICLE; CASE REPORT; DISEASE SEVERITY; DRUG WITHDRAWAL; ENZYME INHIBITION; FEMALE; HUMAN; KIDNEY DISTAL TUBULE; KIDNEY TUBULE ACIDOSIS; METABOLIC ACIDOSIS; VERTIGO;

EID: 21744458078     PISSN: 0004282X     EISSN: None     Source Type: Journal    
DOI: 10.1590/S0004-282X2005000300032     Document Type: Article

References (22)

1. Spina E, Perugi G. Antiepileptic drugs: indications other than epilepsy. Epileptic Disord 2004;6:57-75.
2. Chandramouli J. Newer anticonvulsant drugs in neuropathic pain and bipolar disorder. J Pain Palliat Care Pharmacother 2002;16:19-37.
3. Brandes JL, Saper JR, Diamond M, et al. and MIGR-002 Study Group. Topiramate for migraine prevention: a randomized controlled trial. JAMA 2004;25:965-973.
4. Silberstein SD, Neto W, Schmitt J, Jacobs D; MIGR-001 Study Group. Topiramate in migraine prevention: results of a large controlled trial. Arch Neurol 2004;61:490-495.
5. Krymchantowski AV, Tavares C, Penteado JC, et al. Topiramato no tratamento preventivo da migrânea: experiência em um centro terciário. Arq Neuropsiquiatr 2004;62:91-95.
6. Ozer Y, Altunkaya H. Topiramate induced metabolic acidosis. Anaesthesia 2004;59:830.
7. Tartara A, Sartori I, Manni R, Galimberti CA, Di Fazio M, Perucca E. Efficacy and safety of topiramate in refractory epilepsy: a long-term prospective trial. Ital J Neurol Sci 1996;17:429-432.
8. Fakhoury T, Murray L, Seger D, McLean M, Abou-Khalil B. Topiramate overdose: clinical and laboratory features. Epilepsy Behav 2002;3:185-189.
9. Takeoka M, Riviello JJ Jr, Pfeifer H, Thiele EA. Concomitant treatment with topiramate and ketogenic diet in pediatric epilepsy. Epilepsia 2002;43:1072-1075.
10. Philippi H, Boor R, Reitter B. Topiramate and metabolic acidosis in infants and toddlers. Epilepsia 2002;43:744-747.
11. Levisohn PM. Safety and tolerability of topiramate in children. J Child Neurol 2000;15(Suppl 1):22-26.
12. Montenegro MA, Guerreiro MM, Scotoni AE, Guerreiro CA. Predisposition to metabolic acidosis induced by topiramate. Arq Neuropsiquiatr 2000;58:1021-1024.
13. Stowe CD, Bollinger T, James LP, Haley TM, Griebel ML, Farrar HC 3rd. Acute mental status changes and hyperchloremic metabolic acidosis with long-term topiramate therapy. Pharmacotherapy 2000;20:105-109.
14. Wilner A, Raymond K, Pollard R. Topiramate and metabolic acidosis. Epilepsia 1999;40:792-795.
15. Ko CH, Kong CK. Topiramate-induced metabolic acidosis: report of two cases. Dev Med Child Neurol 2001;43:701-704.
16. Izzedine H, Launay-Vacher V, Deray G. Topiramate-induced renal tubular acidosis. Am J Med 2004;116:281-282.
17. Takeoka M, Holmes GL, Thiele E, et al. Topiramate and metabolic acidosis in pediatric epilepsy. Epilepsia 2001;42:387-392.
18. http://www.fda.gov/medwatch/SAFETY/2003/topamax_dhcp.pdf. Accessed in August 30, 2004.
19. Rose BD. Etiology and diagnosis of type 1 and type 2 renal tubular acidosis. In In Rose BD (ed). Up to date, Wellesley: UpTo Date, 2004.
20. Post TW, Rose BD. Approach to the adult with metabolic acidosis. In Rose BD (ed). Up to date, Wellesley: Up To Date, 2004.
21. Dodgson SJ, Shank RP, Maryanoff BE. Topiramate as an inhibitor of carbonic anhydrase isoenzymes. Epilepsia 2000;41(Suppl 1):35-39.
22. Wiederkehr M, Krapf R. Metabolic and endocrine effects of metabolic acidosis in humans. Swiss Med Wkly 2001;131:127-132.